CareLit · DOI-Nachweis · Klinische Pädiatrie
Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates
DOI 10.1055/s-0043-116334
Bibliografische Angaben
Nachweis in CareLit
Autor:innenN.N.
ZeitschriftKlinische Pädiatrie
Ausgabe05/2017
Jahrgang / SeitenJg. 229 · S. 259-260
Kernaussage aus der Literatur
Abstract-Vorschau
Recent data indicate that the number of children cared for respiratory syncytial virus (RSV) infections in hospitals is in the range of 50,000 to 100,000 per year in the United States 3. Major risk factors include apart from prematurity specifically below 29 weeks, congenital heart defects, Down syndrome and further congenital anomalies. The American Academy of Pediatrics recommended in 2014 a restriction of Paliviz…
Zitieren
Zitierempfehlung
N.N (2017) Palivizumab for prophylaxis of respiratory syncytial virus infections in preterm neonates. Klinische Pädiatrie, 229 (05), 259-260. https://doi.org/10.1055/s-0043-116334
Mit CareLit weiterarbeiten